Re: Farmas USA
Suerte si alguno la lleváis...
Intercept Pharma to update investors on late-stage OCA study in NASH; shares down 11% premarket
Feb. 10, 2017 8:07 AM • SA Editor Douglas W. House
Investors appear a bit skittish over Intercept Pharmaceuticals' (NASDAQ:ICPT) announcement of an update at 8:30 am ET on its Phase 3 REGENERATE study assessing lead product candidate OCALIVA (obeticholic acid) in NASH patients with liver fibrosis. Shares are down 11% on average volumE